Compile Data Set for Download or QSAR
maximum 50k data
Found 8 Enz. Inhib. hit(s) with Target = 'Complement factor B' and Ligand = 'BDBM159102'
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159102(US10093663, Example 4b | US9682968, Example-3)
Affinity DataIC50:  6nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159102(US10093663, Example 4b | US9682968, Example-3)
Affinity DataIC50:  720nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159102(US10093663, Example 4b | US9682968, Example-3)
Affinity DataIC50:  1.40E+3nMAssay Description:Inhibition of human serine protease factor B catalytic domain (D470 to L764 residues) assessed as inhibition of cleavage cobra venom factor (CVF):Bb ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159102(US10093663, Example 4b | US9682968, Example-3)
Affinity DataIC50:  1.40E+3nMAssay Description:Inhibition of human serine protease factor B catalytic domain (D470 to L764 residues) assessed as inhibition of cleavage cobra venom factor (CVF):Bb ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159102(US10093663, Example 4b | US9682968, Example-3)
Affinity DataIC50:  6.00E+3nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159102(US10093663, Example 4b | US9682968, Example-3)
Affinity DataIC50:  6.70E+4nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159102(US10093663, Example 4b | US9682968, Example-3)
Affinity DataIC50:  6.80E+4nMAssay Description:Inhibition of human serine protease factor B by TR-FRET based competition binding assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159102(US10093663, Example 4b | US9682968, Example-3)
Affinity DataIC50:  6.80E+4nMAssay Description:Inhibition of human serine protease factor B by TR-FRET based competition binding assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed